The Future of Overactive Bladder Treatment Market In Healthcare Sector

Posted by Sanyukta K on August 12th, 2022

Increase in number of mergers and acquisitions is anticipated to help the industry boost in the coming years. For instance, in March 2018, Laborie had entered into a 9 million deal to buy Cogentix Medical. The takeover will give Laborie control of devices for treatment of overactive bladder (OAB) and stress urinary incontinence (SUI). Cogentix built its business around a urology portfolio spearheaded by a neuromodulation device to treat overactive bladder and a soft-tissue bulking agent for managing stress urinary incontinence. 

Key Segment Covered:

Pharmacotherapy:

• Fesoterodine
• Tolterodine
• Trospium
• Anticholinergics
• Solifenacin
• Oxybutynin
• Darifenacin

Diseases type:

• Idiopathic Bladder Overactivity
• Neurogenic Bladder Overactivity

Growth in number of product launches is expected to help the industry flourish during the forecast period. For instance, the FDA approved cefiderocol (FETROJA) in patients of 18 years of age or older who have limited or no alternative treatment options, for complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/10908

Major factors affecting the industry include urinary incontinence and aging in women. Moreover, increase in the number of product launches and approvals for generics is expected to fuel the market growth. Various major companies focus on leveraging strategic alliances such as expanding into multiple sectors, which are more sensitive to driving the industry.

Key Benefits:

• The analytical depiction of the global overactive bladder treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global overactive bladder treatment market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the global overactive bladder treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
• The report provides a detailed global overactive bladder treatment market analysis based on competitive intensity and how the competition will take shape in coming years. 

Leading market Players:

• Astellas Pharma, Inc.,
• Pfizer, Inc.,
• Teva Pharmaceutical Industries Limited,
• Allergan, Plc,
• Medtronic plc,
• Mylan N.V.,
• Endo International plc,
• Hisamitsu Pharmaceutical Co., Inc.,
• Sanofi,
• Aurobindo Pharma Limited